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Abstract
Antigen-specific, T cell hybridomas are useful to study the cellular, molecular and functional events, but their generation is a lengthy process. Thus,
there is a need to develop robust methods to generate the hybridoma clones rapidly in a short period of time. To this end, we have demonstrated
a novel approach using major histocompatibility complex (MHC) class II dextramers to generate T cell hybridomas for an autoantigen, proteolipid
protein (PLP) 139–151. Using MHC class II dextramers assembled with PLP 139–151 as screening and sorting tools, we successfully obtained mono
antigen-specific clones within seven to eight weeks. In conjunction with other T cell markers, dextramers permitted phenotypic characterization of
hybridoma clones for their antigen specificity in a single step by flow cytometry. Importantly, we achieved successful fusions using dextramer+ cells
sorted by flow cytometry as a starting population, resulting in direct identification of multiple antigen-specific clones. Characterization of selected
clones led us to identify chemokine receptor, CCR4+ to be expressed consistently, but their cytokine-producing ability was variable. Our work provides a proof-of principle that the antigen-specific, CD4 T cell hybridoma clones can be generated directly using MHC class II dextramers. The availability of hybridoma clones that bind dextramers may serve as useful tools for various in vitro and in vivo applications.
Keywords: T cell, hybridoma, MHC, class II dextramers, Autoreactive T cells
Abbreviations: MHC, major histocompatibility complex; PLP, proteolipid protein; TCR, T cell receptor; LDC, limiting dilution cloning; TMEV, Theiler’s
murine encephalomyelitis virus; CFA, complete Freund’s adjuvant; M.tb, Mycobacterium tuberculosis; RT, room temperature; LNCs, lymph node cells;
IL, interleukin; FBS, fetal bovine serum; Con-A, concanavalin-A; PEG, polyethylene glycol; HAT, hypoxanthine/aminopterin/thymidine; HT, hypoxanthine/thymidine; 7-AAD, 7-aminoactinomycin-D; 3[H], tritiated; CCRs, chemokine receptors; PMA, phorbol 12-myristate-13 acetate; IFN, interferon;
TNF, tumor necrosis factor.

1. Introduction

hybridomas are screened based on cytokine secretion in response to
antigen stimulations, and individual clones are then obtained mainly
by limiting dilution cloning (LDC) (Rock, 1985; Kruisbeek, 2001; Peterson et al., 1999). Other methods include dispersion in soft agar, micromanipulation and flow cytometry (Rock, 1985). All these methods
require expertise with the individual screening systems, making them
both less practical and less desirable. For example, LDC is a labor-intensive, time-consuming procedure, because the cells need to be diluted to a low density (2 to 3 cells/ml), followed by screening of individual clones for their antigen specificity (Rock, 1985; Lefkovits and
Waldmann, 1984). At least 25 such clones must be verified repeatedly
to obtain a single antigen-specific clone, and the entire process to derive antigen-specific hybridoma clones can take up to three months
or longer, or, the fusions may need to be repeated (Rock, 1985; Kruisbeek, 2001). Thus, there is a critical need to develop robust methods
to derive T cell hybridoma clones quickly and efficiently in a shorter
period of time.

T cell hybridomas are useful tools for studying antigen-specific cellular, molecular, and functional events at a monoclonal level (Kubota
and Iwabuchi, 2014; Rock, 1985; Rock and Benacerraf, 1983; Schrader
and Clark-Lewis, 1982; White et al., 2000; Kruisbeek, 2001). Unlike
primary T cell clones, which may eventually lose their antigen specificity over a period of time if left unstimulated, T cell hybridomas
can maintain antigen specificity for extended periods of time because of their inherent ability to grow continuously in cultures (Rock,
1985; White et al., 2000; Kruisbeek, 2001).
T cell hybridomas are generated through fusion of antigen-sensitized effector T cells with mouse thymoma-derived BW5147 αβ T cell
receptor (TCR)−/− cells, leading to the expression of only the TCRs
specific to the fused T cells (Rock, 1985; White et al., 2000; Kruisbeek,
2001; Kubota, 2006). However, the screening procedure for antigen
specificity is a laborious process (Rock, 1985). Generally, CD4 T cell

86

using MHC class II dextramers to generate antigen-specific T cell hybridomas
We previously reported creation of the next generation of major histocompatibility complex (MHC) class II tetramers, designated
“dextramers,” which enabled us to detect and enumerate the precursor frequencies of autoreactive, antigen-specific CD4 T cells in a
variety of systems (Massilamany et al., 2011a, 2014a, 2014b). Structurally, dextramers contain dextran molecules (polymers of glucose),
each carrying up to seven streptavidin moieties to which multiple
biotinylated MHC/peptide monomers can be assembled. Thus, dextramers can engage more TCRs than that could be achieved with
tetramers (Massilamany et al., 2011a). We demonstrated that MHC
class II dextramers exhibited greater sensitivity and specificity than
could be achieved with MHC class II tetramers in several autoantigens, such as proteolipid protein (PLP) 139–151, myelin oligodendrocyte glycoprotein 35–55, and cardiac myosin heavy chain-α 334–
352 (Massilamany et al., 2011a). Using PLP 139–151 dextramers as
screening tools, we have devised a novel approach for rapidly deriving antigen-specific T cell hybridoma clones within 7 to 8 weeks.
Importantly, dextramer-assisted sorting of antigen-specific clones
allowed us to evaluate the expression of T cell markers, TCRs, and
their vβ-usage in a single step by flow cytometry, including cytokine
secretion and chemokine receptor expression.
2. Materials and methods
2.1. Ethics statement
Five-to-six-week-old female SJL/J (H-2s) mice were procured from
the Jackson Laboratory (Bar Harbor, ME, USA) and maintained in
accordance with the animal protocol guidelines of the University
of Nebraska-Lincoln, Lincoln, NE, USA. The study was conducted
in accordance with the National Institutes of Health guidelines for
the use of experimental animals, and the protocols were specifically approved by the University of Nebraska-Lincoln Institutional
Animal Care and Use Committee (permit number: A3459-01; protocol # 999).
2.2. Peptide synthesis and immunization procedures
PLP 139–151 (HSLGKWLGHPDKF) and Theiler’s murine encephalomyelitis virus (TMEV) 70–86 (WTTSQEAFSHIRIPLP) were synthesized on
9-fluorenylmethyloxycarbonyl chemistry (Neopeptide, Cambridge,
MA, USA). TMEV 70–86 peptide previously has been shown to bind
MHC class II allele, IAs molecule in SJL mice (Massilamany et al.,
2010, 2011a, 2011b; Lorenz et al., 1988; Reddy et al., 2003). Thus,
we used TMEV 70–86 as a control peptide for PLP 139–151 in all assays. The peptides were HPLC-purified (N90%), identity-confirmed
by mass spectroscopy, and dissolved in sterile 1× PBS prior to use.
Peptide emulsions involving PLP 139–151 were prepared in complete
Freund’s adjuvant (CFA) containing Mycobacterium tuberculosis (M.tb,
1 mg/ml) H37RA extract (Difco Laboratories, Detroit, MI, USA), and
administered subcutaneously into SJL mice (100 μg/mouse; n = 3)
(Massilamany et al., 2010). At termination, animals were euthanized
using a CO2 chamber prefilled with 2% CO2.
2.3. Generation of MHC class II dextramers
Dextramer reagents comprised of IAs/PLP 139–151 and IAs/TMEV
70–86 (control) were generated as described previously (Massilamany et al., 2011a). We have used IAs/TMEV 70–86 dextramers as
controls to ascertain TCR-binding specificity of IAs/PLP 139–151
dextramers, in all dextramer staining reactions (Massilamany et al.,
2011a). Briefly, the α and β constructs of IAs allele along with the
peptide of interest were expressed together using baculovirus expression systems in SF9 insect cells (Invitrogen, Carlsbad, CA). Soluble MHC class II monomers of IAs were then purified, concentrated,
and biotinylated using biotin ligase (25 μg/10 nmol of substrate;
Avidity, Denver, CO) (Massilamany et al., 2010, 2011a, 2011b). The
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biotinylated monomers were assembled to fluorophore conjugated
dextran molecules (kindly provided by Immudex, Copenhagen, Denmark) at a molar ratio of 20:1 in 1× Tris HCl 0.05M, pH 7.2, by incubating in the dark for 30 min at room temperature (RT) (Massilamany et al., 2011a). The dextramer reagents were aliquoted and
stored at 4 °C until use.
2.4. Generation of antigen-sensitized primary T cells
Ten days post-immunization with PLP 139–151, the draining lymph
nodes (mandibular, axillary, inguinal, and popliteal) were collected
and single cell suspensions were prepared. Lymph node cells (LNCs)
were stimulated with PLP 139–151 (20 μg/ml) at a density of 5 × 106
cells/ml for two days in clone medium (RPMI medium supplemented
with 10% fetal bovine serum [FBS], 1 mM sodium pyruvate, 4 mMLglutamine, 1× each of non-essential amino acids and vitamin mixture, and 100 U/ml penicillin–streptomycin [Lonza, Walkersville, MD])
(Massilamany et al., 2010, 2011b, 2011c). After two days, the cultures
were supplemented with clone medium containing interleukin (IL)-2
(hereafter called IL-2 medium) and maintained for an additional two
days. Viable lymphoblasts were harvested on day 4 and maintained
in IL-2 medium until fusion. In some experiments, LNCs obtained
from immunized mice were expanded with concanavalin-A (Con-A;
1 μg/ml) at a density of 2 × 106 cells/ml for two days before fusion
(Massilamany et al., 2014c).
2.5. Fusion with BW5147 αβ−/− cells
Three approaches were adopted for the generation of antigenspecific T cell hybridoma clones (Figure 1).
2.5.1. Approach 1: derivation of T cell hybridomas using Con-Astimulated T cells generated in immunized mice
LNCs stimulated with Con-A were harvested after 48 h, and cells
were washed twice with DMEM (1× DMEM [HyClone laboratories,
South Logan, UT] containing 10% FBS, 1 mM sodium pyruvate, 7.5
mM L-glutamine, 0.66 M L-arginine [Fisher BioReagents, Fair Lawn,
NJ], 0.27 M L-asparagine [MP Biomedicals, LLC Solon, OH], 24 mM
sodium bicarbonate [Sigma-Aldrich, St. Louis, MO], 10 mM HEPES
[Roche Life Sciences, Indianapolis, IN], and 100 U/ml penicillin–streptomycin, 0.05 mM β-mercaptoethanol [PMD Biosciences, La Jolla,
CA]). Cells were then mixed with BW5147 αβ−/− cells at a ratio of
1:4, washed once, and fused as described earlier (White et al., 2000;
Kruisbeek, 2001; Canaday, 2013; Kohler et al., 1977). The tube containing the cell pellet was placed in a 37 °C water bath, and 0.4 ml of
50% polyethylene glycol (PEG) in 75 mM HEPES (Roche Life Sciences)
was gently added in a circular motion over a 1-minute period. After
stirring the pellet for an additional minute, a total of 10 ml of prewarmed DMEM with 10% FBS (hereafter called hybridoma medium)
was delivered, 1 ml during the first minute, followed by another ml
during the second minute, and the rest (8 ml) during the next 2 min
(1 ml/15 s) as the mixture was gently stirred continuously (White et
al., 2000; Kruisbeek, 2001; Canaday, 2013). After washing with hybridoma medium, cells were plated in 96-well plates at a density of
3.6 × 105 cells/ml (5 × 104 cells/140 μl/well; Figure 1).
2.5.2. Approach 2: generation of T cell hybridomas using antigenstimulated T cells generated in vitro
Viable lymphoblasts were harvested on day 4 poststimulation
with PLP 139–151 and fused with BW5147 αβ−/− cells at a ratio of
1:3; the cells were plated as above in 96-well plates (Figure 1).
2.5.3. Approach 3: generation of T cell hybridomas using the MHC
class II dextramer+ cells sorted by flow cytometry
Viable lymphoblasts were harvested on day 4 poststimulation
with PLP 139–151 and rested in IL-2 medium for two days. Cells
were then stained with the dextramers (IAs/PLP 139–151 and con-
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Figure 1. Approaches to the derivation of T cell hybridomas. Approach 1. LNCs from immunized mice were expanded with Con-A for two days, then
fused with BW5147 αβ−/− cells. Approach 2. LNCs from immunized mice were stimulated with the PLP 139–151 for two days, and the cultures were
then supplemented with IL-2medium. On day 4, viable lymphoblasts were harvested and fused with BW5147 αβ−/−cells. Approach 3. LNCs obtained
from immunized mice were cultured with PLP 139–151 for two days and the cells were supplemented with IL-2 medium. Viable cells were harvested
on day 4, and the cells were rested in IL-2medium for two days. On day 6, cells were stained with dextramers (IAs/PLP 139–151 and control), followed
by a panel of selected TCR vβ antibodies; the double positive cells were then sorted by flow cytometry. After resting in IL-2 medium for 5 days, cells
were fused. Finally, after fusions, cells were plated in 96-well plates, and, after two rounds of HAT selection, visible clones were transferred to 48well plates between days 10 to 12. Cells were then switched to HT medium and screened for antigen specificity using dextramers by flow cytometry.

trol dextramers) in dextramer-staining medium (IL-2 medium containing 2.5% FBS, pH 7.63) at RT for 2 h (Massilamany et al., 2011a).
After washing, PLP 139–151 dextramer-stained cells were incubated
with a cocktail of antibodies for the predominant TCR vβs expressed
by PLP-reactive cells (Massilamany et al., 2011d) (vβ 2, 3, 4, 6, 14 and
17a; BD Pharmingen, San Diego, CA), and anti-CD4 (eBioscience, San
Diego, CA). Cells were then washed and the live CD4+ dextramer+
vβ+ cells were sorted by flow cytometry (FACSAria, BD Biosciences,
San Jose, CA). Cells were washed and rested in IL-2 medium for 5
days, at which time dextramers bound to the cells were no longer
detectable by flow cytometry, leading us to fuse these cells with
BW5147 αβ−/− cells at a ratio of 1:5 in 0.2 ml of PEG. The fused cells
were plated as above in 96-well plates (Figure 1).
Regardless of the approach used, cells in 96-well plates were
supplemented with 2× hypoxanthine/aminopterin/thymidine (HAT;
Sigma-Aldrich) medium (DMEM/20% FBS and 2× HAT) 24 h after fusion and on day 7 postfusion. Between days 10 and 12, visible clones
were transferred from 96-well plates to 48-well plates (Figure 1). The
cells were then gradually deprived of HAT medium by replacing with
hypoxanthine/thymidine (HT; Sigma-Aldrich) medium (DMEM/ 20%
FBS and 1× HT) (White et al., 2000; Kruisbeek, 2001; Canaday, 2013).

oma medium at RT for 1 h (Massilamany et al., 2011a). The cells
were then stained with anti-CD3, anti-CD4, and 7-aminoactinomycin-D (7-AAD) and acquired by flow cytometry. The pools positive
for CD3, CD4, and PLP 139–151 dextramers within the live populations (7-AAD−) were analyzed using FlowJo software (Tree Star, Ashland, OR). The next day, individual wells from the positive pools were
screened again by dextramer staining as above. Because each well
could contain more than one clone with different vβs, cells in each
well were then stained with a panel of anti-mouse TCR vβ antibodies as indicated, along with anti-CD3, anti-CD4, and 7-AAD. After
being washed and acquired by a flow cytometer, vβ+ CD3+ CD4+
T cell hybridoma clones were analyzed in the live (7-AAD−) population. Finally, by using PLP 139– 151 dextramers, and vβ antibodies, cells positive for both were identified. To obtain single clones,
cells stained as above with the specific anti-TCR vβ were sorted with
one cell per well into 96-well plates containing hybridoma medium.
Plates were incubated until visible clones were observed, which occurred between days 10 to 14 postsorting. Positive clones were gradually expanded and reascertained for dextramer positivity. Clones
were labeled appropriately and preserved in liquid nitrogen until
further use.

2.6. Screening of T cell hybridomas for antigen-specificity
and TCR vβ-usage and derivation of antigen-specific T cell
hybridoma clones

2.7. Measurement of proliferative responses

The T cell hybridoma clones were screened for antigen specificity
10 to 12 days after the cells were plated in 96-well plates (Figure
2). Pools of clones were prepared, each pool represented by cells
obtained from 16 wells in a 48-well plate. Cells were washed and
stained with IAs/PLP 139–151 and control dextramers in hybrid-

To assess the functional responsiveness of T cell clones, we used tritiated 3[H]-thymidine-incorporation assay. Briefly, hybridoma clones
were cultured in clone medium in the presence of irradiated (3000
rad) syngeneic LNC/splenocytes pulsed with PLP 139–151 as antigen-presenting cells at a ratio of 1:5 (1 × 104:5 × 104) for 20 h. After
pulsing with 3[H]-thymidine for 16 h, proliferative responses were
measured as counts per minute.

using MHC class II dextramers to generate antigen-specific T cell hybridomas
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2.9. Cytokine measurement
The ability of T cell hybridomas to secrete different cytokines was
assessed by intracellular staining (Massilamany et al., 2010, 2011c;
Evavold et al., 1994; Nakajima et al., 2001; Wilde et al., 1992). Cells
were stimulated with phorbol 12-myristate-13 acetate (PMA, 10 ng/
ml) and ionomycin (150 ng/ml, Sigma-Aldrich) for 5 h in the presence of 1 mM monensin (Golgi stop, BD Pharmingen). After staining with anti-CD4 and 7-AAD, cells were fixed, permeabilized, and
stained with anti-cytokine antibodies or with the respective isotype
controls. After washing, the cells were acquired by flow cytometry,
and the frequencies of cytokine-producing cells were determined in
the live (7-AAD−) CD4 population using Flow Jo software. The clones
of anti-cytokine antibodies used were: IL-2 (JES6-5H4), interferon
(IFN)-γ (XMG1.2), IL-4 (11B11), IL-10 (JES5-16E3), IL-17A (eBio17B7),
and tumor necrosis factor (TNF)-α (MP6-XT22), all from eBioscience.
3. Results and discussion
We demonstrated the utility of using MHC class II dextramers to
create CD4 T cell hybridomas for PLP 139–151 that induce experimental autoimmune encephalomyelitis in SJL (H-2s)mice. The use of
MHC class II dextramers offered few advantages: 1). The dextramers
could be used as screening tools to verify the antigen specificity of
potential clones as early as 10 to 12 days after fusion. In conjunction with other T cell markers (CD3, CD4, CD8, and TCR/vβs) the use
of dextramers allowed us to identify antigen-specific clones by flow
cytometry in a single step. 2). After identifying positive clones, we
could derive mono antigen-specific clones by sorting the cells with
one cell per well using dextramers. 3). Unlike the traditional method
that requires a large number of antigen-sensitized T cells (up to 5 ×
107 cells), successful fusions could be achieved with as few as ~7.6
× 105 dextramers+ cells. Overall, the time required to obtain clones
can be cut down significantly, and all steps from immunizations to
cloning single cells can be finished in 7–8 weeks.
As we reported previously, dextramers were found to be helpful
in detecting the rare antigen-specific, autoreactive CD4 T cells, which
was not possible using tetramers, both ex vivo, and in situ within target organs such as the hearts and brains (Massilamany et al., 2011a,
2014a, 2014b). Unlike MHC class II tetramers that contain no more
than four biotinylated MHC/peptide complexes because only a single streptavidin moiety is available, a large number of MHC/peptide complexes (up to 20) can be assembled to each dextran backbone in dextramers, because multiple streptavidin moieties (6 to 7)
are available for binding the biotinylated MHC molecules (Massilamany et al., 2011a; Batard et al., 2006). As a result, large aggregates
of MHC/peptide complexes can be generated through dextramers,
leading to enhanced avidity for binding to T cells by engaging multiple TCRs. Thus, using dextramers could increase detection sensitivity by at least 5-fold, as compared with use of tetramers (Massilamany et al., 2011a). Although derivation of T cell hybridomas for
PLP 139–151 has been reported previously (Donermeyer et al., 1995;

Figure 2. Screening of T cell hybridomas for antigen specificity. Pools of
cells representing 16 wells in 48-well plates were prepared, and the cells
were stained with IAs/MHC class II dextramers (PLP 139–151 and control). Pools that were positive for PLP 139–151 dextramers were identified, then individual wells containing the dextramer+ cells were identified. Cells in these wells were tested for both TCR vβs and dextramers;
the double-positive cells were sorted by flow cytometry with one cell
per well; and their antigen-specificity was reconfirmed.

2.8. Analysis of chemokine receptor expression
The surface expression of chemokine receptors (CCRs) was analyzed
using antibodies for CCR4, CCR5, or CCR6, anti-CD4, and 7-AAD.
After washing, cells were acquired by flow cytometry, and percentages of chemokine receptor-expressing cells were determined in
the live (7-AAD−) population using Flow Jo software. The clones of
antichemokine receptor antibodies used were CCR-4 (2G12), CCR-5
(HMCCR5) and CCR-6 (29-2L17), all from BioLegend, San Diego, CA.

Table 1. Evaluation of TCR vβ-usage in PLP 139–151 dextramer+ CD4+ T cell hybridoma clones.
Well
ID
A9
A17
A31
D19
D26
E48
H2
H15
I14
I29

Dextramer
staining
+
+
+
+
+
+
+
+
+
+

Panel of TCR vβ antibodies used
vβ2

vβ3

vβ4

−
+
+
+
+
+
+
+
−
+

−
−
−
−
−
−
−
−
+
−

−
+
−
+
−
+
+
+
−
−

vβ5.1/5.2 vβ6
−
−
−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−
+
−

vβ7 vβ8.1/8.2 vβ8.3
−
−
−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−
−
−

vβ9

vβ10b

vβ11

vβ12

vβ13

vβ14

vβ17a

−
−
−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−
−
−

−
−
−
+
−
−
−
−
−
−

+
+
−
+
+
+
−
+
+
−
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Kuchroo et al., 1994), we took advantage of the availability of dextramer reagents for this antigen to demonstrate their utility for deriving antigen-specific T cell hybridomas quickly and efficiently, by
exploring three different approaches (Figure 1).

Table 2. Derivation of PLP 139–151-specific hybridoma clones using PLP
139–151 dextramer+ cells sorted by flow cytometry as the starting population for fusions.

3.1. Approach 1: derivation of T cell hybridomas using Con-Astimulated T cells generated in immunized mice

Well ID

Con-A is traditionally used as a mitogen to stimulate unprimed polyclonal T cell populations that permit assessment of the overall immunocompetence in physiological and clinical conditions (Stone et
al., 2009; Kruisbeek et al., 2004; Krammer et al., 1982). Here, we used
this reagent to expand antigen-sensitized T cells ex vivo with an expectation that they may get enriched upon activation, thus allowing
their availability to be more in number for fusions. We used LNCs
sensitized with PLP 139–151 from immunized mice, and, after expansion with Con-A for two days, cells were fused, expecting that viable
clones could be directly screened by dextramers for their antigen
specificity. The fused cells were plated in ten 96-well plates (10 × 96
= 960 wells), and, after 12 days, successful fusions as indicated by
viability/growth of cells were noted in 30% of the wells (288/960 ×
100). We then made 18 pools, each representing cells from 16 wells
for staining with PLP 139–151 dextramers (Figure 2). Contrary to our
expectations, we did not detect the pools positive for staining with
PLP 139–151 dextramers. Such an outcome was not surprising, however, given the low frequencies of antigen-sensitized T cells present in the ex vivo LNCs populations (Jenkins and Moon, 2012).We
had previously determined the frequency of PLP 139–151-specific
cells to be 0.12% of total CD4 T cells in immunized SJL mice (Massilamany et al., 2011a). We had predicted that Con-A-stimulation
might sufficiently facilitate the expansion of antigen-specific T cells
to allow us to obtain a few clones, but this was not the case. Alternatively, this approach may still prove to be successful if CD4 T cells
enriched from immunized animals are used as a starting population
for fusions, but we did not investigate this possibility.
3.2. Approach 2: generation of T cell hybridomas using
antigen-stimulated T cells generated in vitro
Here, we fused the effector T cells generated from PLP 139–151 immunized mice with BW5147 αβ−/− cells (Rock, 1985; White et al.,
2000; Kruisbeek, 2001). LNCs were obtained from immunized SJL
mice, and after stimulating the cells with PLP 139–151 and resting
them in IL-2 medium, viable lymphoblasts were used for fusions

A3
A9
A13
A18
A22
A36
A38
A47
B2
B11
B12
B13
B16
B27

Dextramer
staining vβ2
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
−
−
+
−
−
−
−
+
−
+
−

Panel of TCR vβ antibodies used
vβ3

vβ4

vβ6

vβ14

vβ17a

−
−
−
−
−
−
−
−
−
−
−
−
−
−

−
+
−
+
+
−
+
−
+
+
−
+
+
−

−
−
−
−
−
+
−
−
−
−
−
−
+
−

−
−
+
−
+
−
−
−
−
−
−
−
−
−

+
+
−
+
−
−
−
−
+
+
+
+
−
+

(Figure 1). We used dextramer reagents (IAs/PLP 139–151, and control) for screening and cloning antigen-specific hybridomas as a
novel strategy in a step-wise fashion (Figure 2).
3.2.1. Step 1
To generate PLP 139–151-specific hybridomas, eight 96-well
plates were plated with the fused cells (8 × 96 = 768 wells). Successful fusions, indicated by viability/growth of cells, were noted in
62.5% of the wells (480/768 × 100). We then made 30 pools, each
consisting of cells from 16 wells, and tested them for staining with
PLP 139–151 dextramers, where TMEV 70–86 dextramers were used
as controls. We randomly picked 8 pools that were positive for PLP
139–151 dextramers. Dextramer staining was then repeated individually using cells from each of the 128 wells (8 pools × 16). This analysis led us to identify at least 10wells that were positive for PLP 139–
151 dextramers (10/128 × 100 = 7.8%) (Table 1).
3.2.2. Step 2
In this step, cells in the dextramer+ wells were screened for TCR
vβ-usage. Since, dextramer+ cells in each well could contain more
than one clone, potentially with different vβ-usage, we decided to
first screen each of the 10 wells of PLP 139–151-dextramer+ clones
with a panel of vβ antibodies. The selected vβ panels were based
on the published literature and our own data (Massilamany et al.,

Figure 3. Generation of antigen-specific, single cell clones by flow cytometry. To obtain single cell clones, cells were stained with IAs/dextramers (PLP
139–151 and control), CD4 and vβ17a or vβ2 antibodies and 7-AAD. Through flow cytometric analysis, PLP 139–151 dextramer+ vβ+ cells were sorted
with one cell per well, and after expansion, their antigen-specificity was reconfirmed by dextramer staining as described above.

using MHC class II dextramers to generate antigen-specific T cell hybridomas
2011c, 2011d; Kuchroo et al., 1992; Whitham et al., 1993). Through
these analyses we identified wells showing positive staining for up
to six vβs for PLP 139–151 (vβ2, vβ3, vβ4, vβ6, vβ14 and vβ17a; Table 1). Of note, for analysis of vβ-expressing dextramer+ cells, it was
critical to stain with dextramers first, followed by staining with vβ
antibodies (Massilamany et al., 2011d). Staining with the above reagents in reverse order allows detection of only vβ+ cells, and as
such, the proportion of dextramer+ cells can be absent or significantly reduced, indicating that vβ-antibodies can sterically hinder
dextramers from binding to TCRs.
3.2.3. Step 3
After identifying the wells positive for both dextramers and specific vβs, we sought to provide a proof-of principle that single cell
clones can be obtained by flow cytometric sorting of dextramer+
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cells. To this end, we selected two wells (A9 and D26; Table 1) and
sorted the cells positive for PLP 139–151 dextramers and anti-vβ17a
or anti-vβ2 respectively with a single cell per well into one 96-well
plate for each. We obtained a total of 31 viable clones, and rescreening of these by dextramer staining led us to identify at least ten
clones to be highly positive for PLP 139–151 dextramers (Figure 3).
3.3. Approach 3: generation of T cell hybridomas using the
MHC class II dextramer+ cells sorted by flow cytometry
In this approach, we asked whether dextramer+ T cells could be
used as a starting population for fusing the cells, expecting the dextramer+ clones to be antigen specific, thus avoiding the multi-step
procedure described in approach 2. We addressed this question
by sorting the antigen-specific CD4 T cells from LNC cultures de-

Figure 4. Phenotypic and functional characterization of selected T cell hybridomas. (a) Surface markers. Three T cell hybridoma clones, specific for
PLP 139–151were selected, and expression of CD3, CD4, CD8, and TCRs was characterized by flow cytometry. (b) Antigen specificity. Antigen specificity of the selected clones was tested by dextramer staining, and proliferative responses as evaluated by flow cytometry and 3[H]-thymidine incorporation assay, respectively. The experimental details are as described in the Materials and methods section. PLP 139–151: specific antigen; TMEV
70–86: control antigen. Representative data from three to four individual experiments are shown.
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Figure 5. Characterization of T cell hybridomas based on the expression of chemokine receptors and cytokines. Three T cell hybridoma clones, specific to PLP 139–151 were evaluated for surface expression of chemokine receptors and cytokine secretion by intracellular staining as described in
the Materials and methods section. Top panel (a) indicates the expression of CCR4, and bottom panel (b) represents cytokine-producing CD4+ cells.
Representative data from three individual experiments are shown.

rived from SJL mice immunized with PLP 139–151. For sorting PLP
139–151-specific cells, we used PLP 139–151 or control dextramers,
anti-CD4, and a mixture of anti-vβs (vβ2, 3, 4, 6, 14 and 17a). We
sorted a total of 7.6 × 105 dextramer+ vβ+ cells by flow cytometry,
and after resting the cells in IL-2-medium for 5 days, the cells were
fused with BW5147 αβ−/− cells, followed by plating in one 96-well
plate. We noted successful fusions as indicated by viable clones in
78 wells (78 / 96 × 100 = 81.3%). A total of 16 pools, each represented by cells from 3 to 5 wells, were then stained with PLP 139–
151 dextramers, leading us to identify 10 positive pools. Cells from
each of 50 wells (10 pools × 5) were then screened for staining with
dextramers leading us to identify at least 14 wells that were positive
for dextramers (14/50 × 100 = 28%), which were then examined for
vβ-expression using selected TCR vβ antibodies, as shown in Table
2. Expectedly, cells in each well showed positive staining for more

than one vβ, suggesting the presence of multiple clones in a given
well (Table 2). Thus, we have provided a proof of principle that antigen-specific T cell hybridoma clones can be obtained using dextramer+ cells as a starting population for fusions.
Overall, the relative successful cell-fusion frequencies obtained
from all the three approaches were in the order of approach 3
(81.3%) followed by approach 2 (62.5%), and approach 1 (30%).
Similarly, screening of these fusions also led us to identify 28% of
wells to contain antigen (PLP 139–151)-specific hybridoma clones
with approach 3 as opposed to 7.8% with approach 2, and none
with approach 1.
After generating the T cell hybridomas for PLP 139–151, we
sought to characterize their phenotypes. We selected three clones
(A9/17, A9/ 23, and A9/24; Figure 3); all of them showed the expression of CD3, CD4 and TCR (Figure 4a). We then evaluated antigen
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specificity based on dextramer staining and proliferative responses.
Expectedly, all PLP 139–151-specific clones could be stained with the
corresponding dextramers but not with control dextramers (Figure
4b: top panel). Next, we asked whether PLP 139–151-specific clones
can functionally respond to antigens. Using 3[H]-thymidine incorporation assay, it was clear that all PLP 139–151-specific clones responded to PLP 139–151 stimulation, but the net outcome was reduced proliferative response likely due to cell death as reported by
others (Donermeyer et al., 1995; Shi et al., 1989, 1990; Waldner et al.,
2000), which occurred only with PLP 139–151 but not with the control antigen (Figure 4b: bottom panel). Thus, we identified functionally responsive clones for PLP 139–151. Finally, we asked whether
the functionalities of antigen-specific T cell hybridomas can be distinguished based on chemokine receptor expression and cytokine
synthesis (Figure 5). By testing for chemokine receptors CCR4, CCR5,
and CCR6 as the putative markers for Th2, Th1, and Th17 phenotypes (Islam and Luster, 2012; Wu et al., 2001), respectively, only
CCR4 was found to be present in all PLP 139– 151-specific clones
(Figure 5a). However, testing for their cytokine producing ability by
intracellular staining revealed that one PLP 139– 151-specific clone
(A9/23) was positive for IL-2 and IL-4, whereas two other clones
(A9/17 and A9/24) showed only marginal production of IL-2 (Figure
5b). None of the clones showed any detectable staining for other
cytokines (proinflammatory cytokines IFN-γ, IL-17A, and TNF-α and
the anti-inflammatory cytokine IL-10; data not shown) indicating
that the cytokine-producing ability of T cell hybridomas is largely
restricted to T cell growth factors. Similar observations have been
made with T cell hybridoma clones specific to various other antigens
(Rock, 1985; Hagiwara et al., 1988).
4. Conclusions
In summary, we have demonstrated the utility of MHC class II dextramers for cloning antigen-specific CD4 T cell hybridomas using
PLP 139–151 as an autoantigen. We have previously reported that
dextramers are expected to bind T cells bearing high-affinity TCRs
and therefore propose that the hybridoma clones obtained by using
dextramers might carry such TCRs. However, in spite of enhanced
detection sensitivity, dextramers cannot detect the complete repertoire of antigen-specific T cells as we previously demonstrated
(Massilamany et al., 2011a). Thus, we cannot conclude that dextramer− clones are not antigen-specific, and the clones possibly expressing the low-affinity TCRs might be undetected by dextramers.
Nonetheless, if MHC class II dextramer-bound T cells are to be interpreted as T cells bearing high affinity TCRs, then the availability
of dextramer-detectable hybridoma clones can serve as useful tools
for various applications, such as screening peptide libraries to identify antigenic epitopes, epitope mimics, altered peptide ligands, and
chemical analogues of activating ligands; studies related to antigen
processing and presentation pathways; production of TCR-specific
monoclonal antibodies; in vivo tracking of antigen-specific T cells;
and other molecular and functional studies that involve interactions
with TCRs (Rock, 1985; Canaday et al., 2003; Depta et al., 2004; Green
et al., 1994; Zumla et al., 1992). One caveat to keep in mind about
dextramer-assisted generation of T cell hybridomas is that the availability of MHC dextramers for antigens of interest is absolutely critical, but their generation per se may be a time-consuming process.
Should the dextramer reagents be made available, then derivation
of T cell hybridomas can be accomplished rapidly in a limited timeframe of 7–8 weeks.
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